Major Depressive Disorder

Here are highlights from the week in Psychiatric Times.

Recent research sheds light on which antidepressants should be preferred as a first option for long-term use.

Here are highlights from the week in Psychiatric Times.

Andrew Krystal, MD, and Wayne Drevets, MD, share their thoughts on the recent seltorexant data presented at the 2024 ASCP Annual Meeting.

A poster presented at the 2024 ASCP Annual Meeting discussed the results of a study on the treatment for depressive symptoms in this patient population.

A poster presented at the 2024 ASCP Annual Meeting discussed the results of a study analyzing the treatment’s safety and efficacy in this patient population.

A poster presented at the 2024 ASCP Annual Meeting discusses the results of a systematic literature review.

Research on MDD treatments seltorexant and Spravato (esketamine) CIII nasal spray shared at 2024 ASCP Annual Meeting.

How can we enhance our lithium research?

Here are highlights from the week in Psychiatric Times.

A more useful measure than BMI or waist circumference? Researchers analyzed the association between weight-adjusted waist index and depressive symptoms.

A recent study analyzed longitudinal data of patients with schizophrenia or major depressive disorder to rank treatment regimens in terms of weight gain, adverse effects, and response to treatment.

The latest in mood disorder news, all in one place.

Here are highlights from the third day of this year’s APA Annual Meeting.

This 2024 APA Annual Meeting poster investigated the relationship between antiobesity agents like semaglutide and depression.

What is new in research on major depressive disorder?

Here are some updates from the world of psychiatry throughout the month of April.

The experts weighed in on a wide variety of psychiatric issues for the April issue of Psychiatric Times.

Here are highlights from the week in Psychiatric Times.

Check out new positive topline data from the SAVITRI study assessing the efficacy and safety of NBI-1065845 in adults with major depressive disorder.

Here are highlights from the week in Psychiatric Times.

What does the recent FDA clearance of this treatment for adolescents mean for the future of MDD treatment?

Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints of a new phase 3 study.

From a look at record-high suicide rates to subspecialty shortages in psychiatry, here are highlights from the week in Psychiatric Times.

From a groundbreaking FDA approval to the hidden toll of COVID-19, here are highlights from the week in Psychiatric Times.

“The selectivity of NBI-1070770 for the NMDA NR2B receptor may benefit patients with moderate to severe depression.”

New phase 2 study initiated to determine the potential of ALTO-203 as an antidepressant in patients with major depressive disorder and anhedonia.

The FDA has cleared the first prescription digital therapeutic for major depressive disorder, Rejoyn.

The experts weighed in on a wide variety of psychiatric issues for the March 2024 issue of Psychiatric Times.

From a promising new intervention for treatment-resistant depression to another look at the STAR*D controversy, here are highlights from the week in Psychiatric Times.